These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition. Maciola AK; La Raja M; Pacenti M; Salata C; De Silvestro G; Rosato A; Pasqual G Front Immunol; 2022; 13():830710. PubMed ID: 35173741 [TBL] [Abstract][Full Text] [Related]
4. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698 [TBL] [Abstract][Full Text] [Related]
5. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects. Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828 [TBL] [Abstract][Full Text] [Related]
6. COVID-19-neutralizing antibodies predict disease severity and survival. Garcia-Beltran WF; Lam EC; Astudillo MG; Yang D; Miller TE; Feldman J; Hauser BM; Caradonna TM; Clayton KL; Nitido AD; Murali MR; Alter G; Charles RC; Dighe A; Branda JA; Lennerz JK; Lingwood D; Schmidt AG; Iafrate AJ; Balazs AB Cell; 2021 Jan; 184(2):476-488.e11. PubMed ID: 33412089 [TBL] [Abstract][Full Text] [Related]
7. Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection. Yao L; Wang GL; Shen Y; Wang ZY; Zhan BD; Duan LJ; Lu B; Shi C; Gao YM; Peng HH; Wang GQ; Wang DM; Jiang MD; Cao GP; Ma MJ J Infect Dis; 2021 Aug; 224(4):586-594. PubMed ID: 33978754 [TBL] [Abstract][Full Text] [Related]
8. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays. Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698 [TBL] [Abstract][Full Text] [Related]
9. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients. Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren HG; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S J Immunol; 2020 Nov; 205(9):2437-2446. PubMed ID: 32878912 [TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity. Kim JY; Kwon JS; Bae S; Cha HH; Lim JS; Kim MC; Chung JW; Park SY; Lee MJ; Kim BN; Jung J; Kim MJ; Shin EC; Kim SH Am J Trop Med Hyg; 2021 Jun; 105(2):395-400. PubMed ID: 34143752 [TBL] [Abstract][Full Text] [Related]
11. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679 [TBL] [Abstract][Full Text] [Related]
12. Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients. Patil HP; Rane PS; Shrivastava S; Palkar S; Lalwani S; Mishra AC; Arankalle VA Viral Immunol; 2021 Apr; 34(3):201-209. PubMed ID: 33656935 [TBL] [Abstract][Full Text] [Related]
13. Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. Butler SE; Crowley AR; Natarajan H; Xu S; Weiner JA; Bobak CA; Mattox DE; Lee J; Wieland-Alter W; Connor RI; Wright PF; Ackerman ME Front Immunol; 2020; 11():618685. PubMed ID: 33584712 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ; J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924 [TBL] [Abstract][Full Text] [Related]
15. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. Cervia C; Nilsson J; Zurbuchen Y; Valaperti A; Schreiner J; Wolfensberger A; Raeber ME; Adamo S; Weigang S; Emmenegger M; Hasler S; Bosshard PP; De Cecco E; Bächli E; Rudiger A; Stüssi-Helbling M; Huber LC; Zinkernagel AS; Schaer DJ; Aguzzi A; Kochs G; Held U; Probst-Müller E; Rampini SK; Boyman O J Allergy Clin Immunol; 2021 Feb; 147(2):545-557.e9. PubMed ID: 33221383 [TBL] [Abstract][Full Text] [Related]
16. Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections. Rijkers G; Murk JL; Wintermans B; van Looy B; van den Berge M; Veenemans J; Stohr J; Reusken C; van der Pol P; Reimerink J J Infect Dis; 2020 Sep; 222(8):1265-1269. PubMed ID: 32726417 [TBL] [Abstract][Full Text] [Related]
17. Long-term monitoring of the development and extinction of IgA and IgG responses to SARS-CoV-2 infection. Ivanov A; Semenova E J Med Virol; 2021 Oct; 93(10):5953-5960. PubMed ID: 34185312 [TBL] [Abstract][Full Text] [Related]
18. Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma. Tso FY; Lidenge SJ; Poppe LK; Peña PB; Privatt SR; Bennett SJ; Ngowi JR; Mwaiselage J; Belshan M; Siedlik JA; Raine MA; Ochoa JB; Garcia-Diaz J; Nossaman B; Buckner L; Roberts WM; Dean MJ; Ochoa AC; West JT; Wood C PLoS One; 2021; 16(3):e0247640. PubMed ID: 33661923 [TBL] [Abstract][Full Text] [Related]
19. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525 [TBL] [Abstract][Full Text] [Related]